![Assay: Irreversible inhibition of rat brain cytosolic MAGL assessed as [3H] - EMBL-EBI](https://cedclinic.com/wp-content/uploads/2026/06/ced-pexels-4226264-1-150x150.jpg "Assay: Irreversible inhibition of rat brain cytosolic MAGL assessed as [3H] - EMBL-EBI 6")
#67 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians need to understand that CBD monotherapy has limited efficacy for most conditions, which challenges the widespread marketing of CBD-only products to patients seeking symptom relief. As research evolves on cannabinoid combinations and ratios, practitioners should stay informed about emerging evidence to counsel patients realistically about what current medical cannabis can and cannot achieve. This knowledge gap directly impacts clinical decision-making and patient expectations, particularly for those considering cannabis as an alternative or adjunctive therapy.
Clinical research increasingly demonstrates that cannabidiol (CBD) monotherapy provides limited therapeutic efficacy for many conditions, suggesting that combination cannabinoid formulations, particularly those including tetrahydrocannabinol (THC), may offer superior clinical outcomes. This finding reflects a shift in prescribing patterns among clinicians who are moving away from CBD-only products toward more balanced or THC-containing formulations based on emerging evidence of synergistic cannabinoid effects. The observation aligns with the “entourage effect” hypothesis, wherein multiple cannabinoids and terpenes work synergistically to produce stronger therapeutic responses than isolated compounds alone. For clinicians, this suggests the need to reassess patient regimens that may be suboptimal on CBD monotherapy and consider evidence-based combination approaches when appropriate and legal within their jurisdiction. Patients currently using CBD-only products with inadequate symptom control should be counseled that alternative formulations may warrant discussion with their prescribing provider, particularly in regions where THC-containing products are accessible. Clinicians should remain informed about emerging cannabinoid pharmacology to make informed, individualized recommendations that optimize therapeutic benefit while balancing legal and safety considerations.
“We’re seeing early signals that CBD monotherapy has limitations for many conditions, and emerging data suggesting that whole-plant formulations or THC-CBD combinations may offer better outcomes, but we need rigorous, large-scale human trials before we can make confident dosing recommendations to patients.”
💊 The clinical use of isolated cannabidiol without concurrent THC presents a practical challenge that mirrors broader limitations in cannabis-based medicine: while CBD offers a favorable safety profile and shows promise for certain conditions like seizure disorders, evidence suggests that THC-CBD combinations or whole-plant formulations may be more therapeutically effective for many conditions, though this benefit comes with increased side effects and abuse potential. The reluctance of clinicians to prescribe high-THC products reflects legitimate concerns about dependence, cognitive effects, and regulatory uncertainty, yet emerging research indicates that optimal cannabinoid ratios may vary significantly by indication and patient population. Healthcare providers should recognize that current clinical evidence remains heterogeneous and often derives from small studies with variable methodology, making individualized treatment decisions difficult and highlighting the need for more rigorous comparative effectiveness research. Until clearer guidance emerges from high-quality trials, a pragmatic approach involves starting with lower-dose, better-studied formulations
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
